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CLINICAL TRIAL ENROLLMENT IN A MULTIDISCIPLINARY PROSTATE CANCER 
CLINIC 
 
Publication No. ______________ 
 
Delora Alyce Domain, MS, BS 
Supervisory Professor: Thomas Buchholz, MD 
Purpose: Clinical oncology trials are hampered by low accrual rates.  Less than 5% of adult 
cancer patients are treated on a clinical trial.  We aimed to evaluate clinical trial enrollment 
in our Multidisciplinary Prostate Cancer Clinic and to assess if a clinical trial initiative, 
introduced in 2006, increased our trial enrollment. 
Methods: Prostate cancer patients with non-metastatic disease who were seen in the clinic 
from 2004 to 2008 were included in the analysis.  Men were categorized by whether they 
were seen before or after the clinical trial enrollment initiative started in 2006. The initiative 
included posting trial details in the clinic, educating patients about appropriate clinical trial 
options during the treatment recommendation discussion, and providing patients with 
documentation of trials offered to them.  Univariate and multivariate (MVA) logistic 
regression analysis evaluated the impact of patient characteristics and the clinical trial 
initiative on clinical trial enrollment. 
Results: The majority of the 1,370 men were white (83%), and lived within the surrounding 
counties or state (69.4%).  Median age was 64.2 years.  Seventy-three point five percent 
enrolled in at least one trial and 28.5% enrolled in more than one trial.  Sixty-seven percent 
enrolled in laboratory studies, 18% quality of life studies, 13% novel studies, and 3.7% 
 vi	  
procedural studies.  On MVA, men seen in later years (p < 0.0001) were more likely to 
enroll in trials.  The proportion of men enrolling increased from 38.9% to 84.3% (p<0.0001) 
after the clinical trial initiative.  On MVA, older men (p < 0.0001) were less likely to enroll 
in clinical trials.  There was a trend toward men in the high-risk group being more likely to 
participate in clinical trials (p = 0.056).  There was a second trend for men of Hispanic, 
Asian, Native American and Indian decent being less likely to participate in clinical trials (p 
= 0.054). 
Conclusion: Clinical trial enrollment in the multidisciplinary clinic increased after 
introduction of a clinical trial initiative.  Older men were less likely to enroll in trials. We 
speculate we achieved high enrollment rates because 1) specific trials are discussed at time 
of treatment recommendations, 2) we provide a letter documenting offered trials and 3) we 
introduce patients to the research team at the same clinic visit if they are interested in trial 
participation.  
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Introduction 
Prostate Cancer 
Prostate Cancer (PCa) is a tumor of the prostate gland that occurs when normal 
glandular cells mutate into malignant cancer cells whose growth, function, and proliferation 
is no longer under the body’s regulatory control.  The majority of prostate cancers are 
adenocarcinomas, an epithelial cancer that originates within glands and/or glandular tissue 
(Crawford, 2009).  However, a small percentage can develop from aberrant squamous cells, 
signet ring, transitional cells or even neuro-endocrine stem cells all normally found in the 
prostate (Bracarda, et al., 2005).  PCa is more likely to be a quiescent localized disease with 
a protracted course but it can also manifest as a rapidly progressing tumor with high 
metastatic potential (Crawford, 2009).  PCa tends to be a highly heterogeneous disease.  
This is partly due to the biology and morphology of the prostate gland.   
The prostate gland itself is an integral part of the male genitourinary system, located 
in the pelvic cavity, nestled between the urinary bladder and the rectum.  It is responsible for 
the production and storage of seminal fluid and is typically classified into 3 different zones: 
central, transition and the peripheral zone.  Although the tumor may originate in one specific 
zone of the prostate, the majority of these tumors have multiple separate copies scattered 
throughout all three zones of the prostrate (Crawford, 2009).  Because of this, prostate 
cancers are considered by convention to be multifocal/multi-centric tumors.  Furthermore, 
these multicentric lesions can and often do have differing glandular patterns and degrees of 
tumor cell differentiation (Bracarda et al., 2005).  Localized prostate tumors tend to spread 
first to the seminal vesicles, urinary bladder and the surrounding tissues (Bracarda et al., 
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2005).  Prostate tumors metastasize primarily to the bone, via the lymphatic system or direct 
hematogenous (Bracarda et al., 2005). 
 
Prevalence and Incidence 
 One in 6 men over the age of 50 will be diagnosed with PCa in their lifetime; of 
these, 1 in 33 will die of the disease (Weissbach et al., 2009).  Despite this seemingly 
moderate death rate, studies show that PCa is second only to lung caner in cancer-related 
mortality in men (Jemal et al., 2010).  The American Cancer Society reported 217,730 
newly diagnosed cases of PCa and 32,050 deaths in the US in 2010 alone (Rosenberg et al., 
2010; Jemal et al., 2010).  The incidence of PCa has been on the rise since 1975 starting at 
195 cases per 100,000 and spiking in 1992 to nearly 250 per 100,000 (Jemal et al., 2010).  
This increase is mostly due to the advent of prostate-specific antigen (PSA) screening, 
which was implemented in the late 1980s (Bracarda et al., 2005).  Its widespread use leveled 
off by the early 2000s, coinciding with the leveling off PCa incidence rates (Bracarda et al., 
2005).  As of 2010, the US incidence of PCa was 155.5 cases per 100,000 (Jemal et al., 
2010).  Screening and early detection have driven the mortality rates down.  Currently, the 
5-year survival rate for PCa approaches 100%, while the 10-year survival rate is 93% 
(Rosenberg et al., 2010).  PCa is a significant problem in the population at large.  One way 
to combat the problem is to learn more about the disease through education and research.   
 
Screening and Diagnosis 
Prostate-specific antigen (PSA) is a glycoprotein produced by the epithelial cells of 
the prostate gland, and is mainly concentrated within the prostate gland (Greene et al, 2009).  
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Serum PSA level is very low in an individual with normal prostate function, however 
aberrant changes in the functionality and integrity of the prostate often gives rise to leakage 
and elevated levels of PSA in the blood.  Because of positive correlation between serum 
PSA level and prostate abnormalities, serum PSA screening has been implemented as a 
diagnostic and/or prognostic biomarker for prostate cancer.   PSA screening guidelines vary 
across different medical organizations.  As of 2009, the age at which the American 
Urological Association (AUA) recommends individuals obtain a baseline PSA has been 
lowered from 50 years to 40 years for those at an average risk (non-African-American, no 
family history) of prostate cancer development (Greene et al., 2009).  Thereafter, individuals 
are recommended to return for regularly scheduled PSA tests (Greene et al, 2009).   
PSA, while being specific to the prostate gland, is not necessarily sensitive only to 
PCa (Bracarda et al., 2005).  Because elevated serum PSA is also highly characteristic of 
non-cancerous prostate abnormalities (ex. prostatitis, benign prostate hyperplasia, etc.), a 
digital rectal examine (DRE) is recommended in conjunction with a screening PSA test 
(Bracarda et al., 2005).  In the presence of an abnormal DRE and/or an elevated PSA, a 
positive prostate biopsy is required for a differential diagnosis (Greene et al., 2009).  A 
review of all possible contributing factors such as PSA density and velocity, prostate size, 
patient age and ethnicity, co-morbidities and previous prostate biopsy is also recommended 
(Horwich, et al., 2010).   
 
Risk Group 
The inherent heterogeneity of prostate tumors necessitates an unique scoring system.  
In addition to the standard TNM (Tumor, Node, Metastasis) staging for solid tumors, 
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prostate cancers are subjected to the disease-specific Gleason score.  The Gleason scoring 
system is based specifically on the glandular pattern of the tumor and the degree of 
differentiation of the tumor cells themselves (Bracarda et al., 2005).  Tumors are stratified 
into five different grades (1-5), with grade 5 having the worse prognosis (Bracarda et al., 
2005).  The two most prominent grades of disease are added together to give a single 
Gleason score which would then be used as a prognostic indicator.  Unfortunately, Gleason 
scores are only useful in scoring adenocarcinomas of the prostate.  This tends not to be an 
immediate concern since approximately 95% of prostate cancers are adenocarcinomas 
(Bracarda et al., 2005).   
Based on PSA level, Gleason score, and T-stage clinically localized tumors are 
further categorized into prognostic recurrence risk groupings (Horwich et al., 2010).  [See 
Table 1 for the NCCN (National Comprehensive Cancer Network) risk group criteria.]  Risk 
group predicts the likely treatment outcome and guides the physician in making the 
appropriate treatment recommendations.   Risk group is also a key factor in the majority of 
interventional clinical trials inclusion/exclusion criteria.  Clinicians/Investigators also 
consider patient age and life expectancy, co-morbidities and general health status (Horwich 
et al., 2010). 
Table 1.  NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer risk group criteria, 
Version 1. 2010. 
Very Low 
Risk Low Risk 
Intermediate 
Risk High Risk 
Very High 
Risk Metastatic 
T1a 
Gleason ≤6 
PSA <10 
ng/mL 
< 3 + biopsy 
cores w/ 
≤50% cancer 
PSA density 
<0.15 ng/mL 
T1 – T2a 
Gleason 2-6 
PSA <10 
ng/mL 
T2b - T2c or  
Gleason 7 or 
PSA 10-20 
ng/mL 
 
T3a or 
Gleason 8 – 
10 
Or PSA >20 
ng/mL 
(locally 
Advanced 
disease) 
T3b – T4 
(locally 
advanced 
disease) 
Any T, N1 
Any T, Any 
N, M1 
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Treatment Options and Side Effects 
Active surveillance consists of identification of prostate cancer patients with low or 
very low risk disease who are then put on a periodic disease monitoring/re-staging schedule 
until such time as a PSA test, DRE or other clinical indicator of progression crosses the risk 
threshold, indicating the need for active treatment (Large et al., 2009).  The main drawback 
associated with the active surveillance approach is increased patient anxiety caused by the 
psychosocial burden of living with an untreated cancer that may or may not have the 
potential to progress and become life threatening (Andrew et al., 2010).   
Radical prostatectomy (RP) is the surgical removal of the prostate gland (Andrew et 
al., 2010).  Along with the normal post-operative complications (i.e. pain, bleeding) RP 
carries with it the threat of stress or total urinary incontinence, and erectile dysfunction 
(possibly long-term) (Andrew et al., 2010).  
Brachytherapy is the insertion of radioactive isotopes seeds into the prostate gland, 
which would deliver a steady dose of therapeutic radiation to the tumor site and surrounding 
tissues over time.  Brachytherapy can be done with either temporary implants or permanent 
ones (Horwich et al., 2010).  The risk group generally determines whether the patient will 
receive temporary or permanent implants.  External beam radiotherapy is radiation therapy 
that originates from a source outside the body.  External beam radiotherapy uses a rotating 
machine (gantry) to aim the radiation at the site of the patient’s cancer, in this case, the 
prostate gland.  Radiation treatment(s), whether it is external beam therapy or internal seed 
implants, all carry the similar side effect profile: bladder, urethra or rectal irritation, frequent 
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urination, burning urination and stronger urges to urinate, rectal soreness or bleeding, and 
frequent bowel movements (Andrew et al., 2010).   
Hormone therapy in the context of prostate cancer treatment consists of Androgen 
Deprivation Therapy (ADT).  ADT is generally a drug given to patients that reduces the 
production and/or effects of androgenic hormones (i.e. testosterone) by preventing the 
cancer cells from interacting with testosterone.  This results in tumor shrinkage because 
many prostate cancers require testosterone for growth and proliferation.  LHRH (luteinizing 
hormone-releasing hormone) agonists are drugs that work indirectly by inducing the 
pituitary gland to release LHRH which cause the testicles to halt the production of 
testosterone.  Orchiectomy is the surgical removal of the testicles, which in turn guarantees a 
substantial and permanent halt to testosterone production.  The timing for giving hormone 
therapy may vary (adjuvant, neo-adjuvant, post-relapse, post-metastasis) (Horwich et al., 
2010).  All hormone therapies cause the same general side effects: impotence, weakness and 
loss of muscle mass, osteoporosis, shrunken testicles (absent testicles in the case of 
orchiectomy), and depression, low self-esteem, loss of aggressiveness/alertness, weight 
gain/obesity and diabetes (Andrew et al., 2010).  In recent years, there is some indication 
that hormone therapy in men with prostate cancer can increase the risk of cardiovascular 
disease and cardiovascular events (i.e. myocardial infarction) (Schwandt et al., 2009) 
 
Two emerging therapy options for PCa that have been in the spotlight in recent years 
are cryotherapy and HIFU.  Both are focal therapies and still under interventional 
investigation.  Focal therapy is loosely defined as any form of incomplete prostate ablation 
therapy (i.e. hemi-ablation, three quarter’s ablation) (Eggener et al., 2010).  The overall  
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Table 2: NCCN Practice Guidelines in Oncology, PCa Initial Treatment Recommendations, version 
1. 2010. 
Risk Group Life Expectancy 
Initial Therapy 
Recommendation 
Adjuvant Therapy 
Recommendations 
Note: The NCCN believes that the best management for any cancer patient is in a clinical trial.  Therefore, 
participation in clinical trials is highly encouraged. 
Very Low Risk < 20yrs 
AS 
PSA every 6 months 
DRE every 12 months 
 
<10 
 
AS 
PSA every 6 months 
DRE every 12 months 
 
AS 
PSA every 6 months 
DRE every 12 months 
Biopsy every 12 months 
 
 
 
 
RT  
Observation or RT 
Low Risk 
≥10 
RP ± PLND If + lymph nodes: 
Observation or ADT 
AS 
PSA every 6 months 
DRE every 12 months 
 
 
 
RT ± short term ADT 
±Brachytherapy 
 
Observe or RT 
<10 yrs 
RP ± PLND If + lymph nodes: 
Observe or ADT 
Observation or RT 
RP ± PLND If + lymph nodes: 
Observation or ADT 
Intermediate Risk 
≥10yrs RT 
± short term ADT 
± Brachytherapy 
 
RT + long term ADT  
Observation or RT High Risk 
 
RP + PLND If + Lymph nodes: 
Observation or ADT 
RT + long term ADT  
Observe or RT 
RP + PLND If  + Lymph nodes: 
Observation or ADT  
Very High Risk / Locally 
Advanced 
 
ADT  
Metastatic 
Any T, N1 
ADT 
Or 
RT + short term ADT 
Metastatic 
Any T, Any N, M1 
 
ADT 
 
AS = Active surveillance, ADT = Androgen deprivation therapy, DRE = Digital rectal exam, RT = Radiation 
therapy, RP = Radical prostatectomy, PLND = Pelvic lymph node dissection. 
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objectives of focal therapy are to a) selectively ablate tumor cells/tissue, b) preserve organ 
function, and c) minimize treatment morbidity (Karavitakis et al., 2010).   
Cryotherapy, more colorfully known as “the male lumpectomy”, is the localized 
destruction of tissue using alternating cycles of extreme freezing and thawing (Lindner et al., 
2010, Lecornet et al., 2010).  Cryotherapy is already known to have many advantages.  It is 
a one-time (often outpatient) treatment, which can be repeated as both a focal and a whole 
gland treatment if necessary (Singh et al., 2010).  However, it does carry with it the 
worrisome risk of erectile dysfunction (Singh et al., 2010).  Other known side effects of the 
treatment are urethral fistula, urethral sloughing and incontinence, although the rates of 
these effects are relatively low (Singh et al., 2010).  
HIFU (High intensity focused ultrasound) therapy is the use of a tightly focused 
ultrasound frequency (between 0.8 and 3.5 MHz) to generate high energy density which 
when aimed at a specific point in the prostate gland causes heating, protein denaturation, 
coagulative necrosis and ultimately tissue death/damage (Lecornet et al., 2010; Eggener et 
al., 2010).   Its use is associated with varying rates of the following side effects: urethral 
strictures, urethro-rectal fistulas, urinary incontinence and impotence (Eggener et al., 2010).  
Further observations and interventional studies of focal therapies need to be completed to 
report on the full potential and/or limitations of both HIFU and cryotherapy.  However, low 
accrual rates on clinical trials have slowed efforts to refine these emerging therapies. 
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Risk Factors and Etiology 
 To date, no direct cause of PCa has been clearly identified.  Studies have suggested a 
plethora of possible contributing factors (previous diagnosis of benign prostatic hyperplasia, 
history of vasectomy, level of sexual activity, weight and diet, smoking, deficiency in 
vitamin E or D, alcohol consumption etc.) but none of these have stood firm against rigorous 
scientific investigation (Bracarda et al., 2005).  However, there is consistent, corroborative 
evidence to support several recognized risk factors that contribute to the development of 
PCa: age, race, a positive family history, and a hereditary pre-disposition. 
Studies and statistics show that the risk of prostate cancer increases with increasing 
age.  According to statistical analysis run on cancer-free US males from 2004 to 2006, from 
birth to age 39, the probability of being diagnosed with PCa is only 1 in 9,422 (Jemal et al, 
2010).  For ages 40 to 50, the probability increases to 1 in 41, for ages 60 to 69 the 
probability is 1 in 16, and for males 70 or older the probability of developing prostate cancer 
peaks at 1 in 8 (Jemal et al, 2010).   Additionally, the American Cancer Society states that 
63% of PCa cases diagnosed in the US occurred in patients 65 years or over (Mordukhovish 
et. al., 2010)  
Tumor cells, whether they originate from prostate tissue or another neoplastic source, 
develop as a result of certain genetic alterations (mutations) in key genes or transcription 
factors involved in regulatory pathways controlling cell growth, proliferation, and function.  
With each round of a cell’s replicative lifespan, dividing cells accumulate or are at risk of 
accumulating gain-of-function or loss-of-function mutations which can damage or alter the 
cell cycle in such a way that promotes neoplastic transformation. Cancerous cells are 
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unlikely to develop as a result of any one mutation.  Even mutations in proto-oncogenes 
(gene whose mutation or increased expression has a high potential to cause cancer) often 
require some corroborating mutation, infection, or environmental factor to express its full 
neoplastic potential.  However, with increasing age, the cells undergo countless rounds of 
replication, each of which has the potential for mutations and transcriptional errors to occur.   
Increasing age ensures, that given enough time, the ‘lethal’ combination of aberrant cells or 
a key mutation in a proto-oncogene will cause a neoplastic transformation. 
There is also a well-established hierarchy of risk for prostate cancer seen among the 
different ethnicity groups (see figure 1).  In the US, the observed incidence of prostate 
cancer is markedly lower in Asian/Pacific Islanders and Native Americans/Alaska Natives at 
approximately 83 cases per 100,000 as compared to Caucasians males at 146.3 cases per 
100,000 (Jemal, 2010).  The PCa incidence among Hispanic/Latino Americans (131.4 cases 
per 100,000) is lower in comparison to Caucasian males but higher in the hierarchy than 
Asian/Pacific Islanders and Native Americans/Alaska Natives (Jemal et al., 2010).  
Meanwhile, African-American men have the highest incidence of PCa at 231.9 cases per 
100,000 (Jemal et al., 2010).  A similar risk hierarchy is observed in PCa death rates among 
the different racial/ethnic groups (see figure 2). 
Ironically, racial and ethnic minorities are under-represented among clinical trials 
participant populations, particularly African-Americans and Hispanics/Latinos (Pinsky et al., 
2008).  Few comparisons have been compiled in which the data includes the 
Hispanic/Latino, Asian/Pacific Islander, or American Indian/Alaska Native groups in 
numbers significant enough to generalize.  Because of this accrual/enrollment disparity, the 
discussion below will focus mainly on the Caucasian--African-American dichotomy.
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Overall, African-Americans are approximately 1.4 times more likely to develop PCa 
than Caucasian men, the next highest ethnic group (Chornokur et al., 2010).  SEER (the 
Surveillance, Epidemiology, and End Results Program) found similar racial disparities in  
PCa incidence rates for African-American and Caucasian males (Mordukhovich et al., 
2010).  Not surprisingly these disparities are carried over into the prognosis, treatment and 
 
 
Figure 1:  Age-adjusted prostate cancer incidence rates per 100,000 population, stratified by 
race/ethnicity, United States, 2002 – 2006. 
 
 
 
.  
Figure 2:  Age-adjusted prostate cancer mortality rates per 100,000 population, stratified by 
race/ethnicity, United States, 2002 – 2006
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PCa specific mortality rates.  A greater percentage of African-American males are diagnosed 
at later stages as compared to Caucasians males; Six percent of African-Americans have 
distant metastasis at initial diagnosis vs. only 4% of Caucasians (Mordukhovich et al., 
2010).  CDC (Centers for Disease Control and Prevention) indicates that African-American 
males have an earlier onset of disease, on average being diagnosed with PCa 3 years earlier 
than Caucasian males (Chornokur et al., 2010).  Furthermore, a cohort study performed on 
37 African-American PCa patients and 35 demographically matched Caucasian patients, 
each receiving radical prostatectomy, showed that the percentage of African-American 
males whose Gleason score was pathologically up-staged post-surgery was nearly double 
that of Caucasian patients (49% vs. 26% respectively) (Chornokur et al., 2010).  The study 
also observed that African-American patients tended to have greater tumor volume, and 2.8 
times more tumor per ng/ml of serum PSA than their Caucasian counterparts (Chornokur et 
al., 2010).    
The basis for these disparities is largely unknown, however, several viable 
hypotheses have been purposed and explored by researchers.  Some suggest that the 
disparity between African Americans and Caucasians is due to lapses in the patterns and 
quality of care (Barocas, et al., 2010).  In studies looking at racial disparities in PCa and the 
possible causes, it is observed that African-Americans are less likely to received radial 
prostatectomy (a definitive, curative therapy) and more likely to receive radiotherapy or 
watchful waiting (a delay of active treatment until such time as tumor progression is 
detected) (Chornokur et al., 2010).  These treatment decisions are possibly due to different 
values and concerns among African-American men regarding the effects of invasive therapy 
such as urinary dysfunction and long-lasting sexual impairment.  Some studies suggest that 
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the reason for these patterns, particularly those observed in African-Americans vs. 
Caucasians are more a reflection of socio-economic disparities such as income, education, 
health insurance and employment status (Barocas et al., 2010).  There are a larger 
percentage of African-American men that are unemployed (15.5% vs. 8.8% of Caucasians), 
below the poverty line (24% vs. 8.6% of Caucasians), and without health insurance (19.5% 
vs 10.4% of Caucasians) (Barocas et al., 2010). 
A second theory points instead to hereditary pre-disposition or ethnicity-specific 
biologic differences to explain racial disparities (Chornokur et al., 2010).  GWAS studies, 
which have been undertaken to search for causal or risk-baring genomic locations which 
confer a hereditary pre-disposition to PCa development, have shown that certain SNPs 
(single nucleotide polymorphisms) associated with PCa risk vary by race (Liu et al., 2011).  
(Of note: of the 71 subgroups examined in the study, only 2 were of Asian descent and 4 of 
African American descent.) (Liu et al., 2011).  Results showed that some risk SNPs are only 
significantly associated with PCa in European populations, likewise others are only 
significant among Asians populations or African-American populations (Liu et al., 2011).  
This suggests that the racial hierarchy observed in PCa incidence, prognosis and survival has 
a basis in genetics and other biologic factors.  It could be that certain; as yet unidentified, 
ethnicity-specific biologic factor(s) are what drive some tumors to develop more 
aggressively than others.  Conversely, it has also been observed that PCa incidence rates in 
Japanese men who immigrated to the United States were noticeably elevated in comparison 
to Japanese men still residing in their native country (Crawford, 2009).  This would seem to 
suggest an environmental risk factor were at heart of racial disparities seen in PCa.  There is 
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also the possibility that several interlocking social, economic, and/or biologic factors would 
best explain the racial hierarchy as opposed to a singular cause. 
In addition to age and race, having a positive family history of PCa is a consistently 
observed risk factor for PCa development.  Case control studies done on African-American 
populations in Jamaica and Caucasian populations in Canada both reveal significant results 
among first-degree relatives.  In the Jamaican study, pedigrees and family history 
information were obtained from histologically proven cases and their demographically 
similar controls (Glover et al., 1998).  Individuals with a first degree relative with a history 
of PCa were twice as likely to develop prostate cancer as individuals without a positive 
family history (Glover et al., 1998).  Among 263 cases, 30 patients had a father, son or 
brother who also had PCa compared to only 15 of 263 controls (Glover et al., 1998).  A 
threefold difference was observed when examining more distant relatives.  Nine cases had a 
grandfather, grandson or uncle with PCa compared with only 3 controls with an affected 
second-degree relative (Glover et al., 1998).  In the Canadian study there were 640 PCa 
cases and 639 demographically similar controls (Ghadirian et al., 1997).  Fifteen percent 
(94) of cases self-reported one or more relatives (father or brother or both) with a history of 
PCa while only 5% (32) of controls revealed first degree relatives with a history of PCa 
(Ghadirian et al., 1997).  Again, a threefold difference is observed, suggesting that PCa does 
indeed ‘run in the family’.  
A U.S. study evaluated a cohort of 15,924 veteran twin pairs (31,848 individuals); 
one thousand nine cases of PCa were identified within the cohort (Page et al., 1997).  
Researchers found that 15.7% of monozygotic twins (MZ) showed pairwise concordance (of 
PCa) in comparison to only 3.7% of dizygotic twins (DZ) (Page et al., 1997).  Probandwise 
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comparison revealed a 27.1% concordance rate for PCa in MZ twins over the 7.1% seen in 
DZ twins (Page et al., 1997).  This means a MZ twin whose brother was diagnosed with PCa 
would have a fourfold higher likelihood of having PCa than a DZ twin whose brother had 
been diagnosed with PCa (Page et al., 1997).  Not surprisingly, the heritability (the 
component of the total variation that is due to genetic factors) of PCa was approximately 
57% (Page et al., 1997).   Environmental factors are thought to account for the remaining 
43%. 
These and other studies done on the etiology and genetic epidemiology of PCa have 
led scientists to classify prostate cancer into three distinctive types:  sporadic, familial, and 
hereditary PCa (Sacco et al., 2005).   Sporadic PCa is defined as occurring randomly within 
any given population, while familial PCa is defined as the observation of unpredictable 
clustering of PCa among relatives.  Hereditary PCa is defined generally as having an earlier 
onset (an average of 6-7 years earlier) and very strong clustering pattern in families (Sacco 
et al., 2005).  The evidence remains conflicting as to what specific pattern of inheritance is 
responsible for hereditary PCa.  However, studies have consistently shown that family 
history is an important risk factor in both familial and hereditary PC.  Further research is 
needed to identify and/or clarify the exact hereditary mechanisms and components that are 
integral to predicting the risk, inheritance and development of PCa. 
 
Significance and Specific Aims 
Despite the significant impact of prostate cancer on the population at large, very little 
research have been dedicated to identifying factors influencing participation in prostate 
cancer-specific clinical trials critical to the development and implementation of new and/or 
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improved diagnostic and therapeutic interventions.  Also, unfortunately, clinical oncology 
trials aimed towards developing new interventions have been hampered by historically low 
accrual rates.  Poor accrual and retention threaten the validity of and power supporting the 
study outcomes.  Studies looking at clinical trials accrual patterns in oncology consistently 
show that clinical trial enrollment for adult cancer patients is dismally low at just 2 – 4% of 
all diagnosed patients (Movsas et al., 2007; Mills et al., 2006; Lara et al., 2001).  However, 
much of the literature reporting accrual statistics on clinical trials participation is not specific 
to prostate cancer.  The majority is either generalized to include multiple neoplastic sites or 
narrowed to investigate the accrual patterns and difficulties of an individual study or a 
limited demographic cohort.   
Gross et al (2005) looks at the effects of sociodemographics, the protocol factors and 
the recruitment center have on enrollment of older patients onto (breast, lung, colorectal and 
prostate) oncology protocols.  Pinsky et al (2008) conducts a similar study, looking at the 
enrollment of racial and ethnic minorities in a prostate, lung, colorectal, and ovarian cancer 
screening trial.  Hoyo et al (2003) focused specifically on barriers and strategies for 
improving enrollment on to prostate cancer protocols, however, the cohort is restricted to 
African-Americans.   
On the broad end of the spectrum, Movsas et al (2007) examines clinical trial 
enrollment patterns in oncology trials as a whole.  Steinhauser et al. (2006) takes it a step 
further and reports on the difficulties of recruiting and retaining patient participation on 
longitudinal research aimed toward a large-body of serious illnesses including: late-stage 
cancers, advanced congestive heart failure, and advanced chronic obstructive pulmonary 
disease.  Craig et al. (2010) and multiple studies conducted by Gross et al (2004, 2005) 
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examine the effect of managed healthcare and new reimbursement policies on all clinical 
oncology trial enrollment.   
Other studies take a narrow approach.  Many look at the successes and difficulties of 
recruitment and accrual on specific, individual oncology trials.  For example, Wallace et al. 
(2006) reports on the accrual outcomes of a surgical prostatectomy vs. radiation 
intervention, while, Heiney et al (2010) details the successful recruitment methods used to 
accrue patients onto a PCa behavioral intervention trial.  Only two studies were found to 
focus specifically on factors influencing enrollment in prostate cancer clinical trials.  A 
Canadian survey study reported on the most influential factors that patients believe drive 
their decision to participate in prostate cancer protocols (Davison et al., 2008).  A second 
family-oriented study analyzed the difficulties of enrollment and retention of PCa patients 
and their significant others, but only on one specific prostate cancer longitudinal randomized 
study (Northouse et al., 2006). 
Because prostate cancer often has a more indolent course and thus a lower risk of 
death especially among older men (>75 years of age) there may be unique factors driving 
patient enrollment in prostate cancer clinical trials.  The aim of this study is to evaluate 
clinical trial enrollment in the Multidisciplinary Prostate Cancer Clinic at UT MD Anderson 
Cancer Center and to assess if a clinical trial initiative, introduced in 2006, increased our 
trial enrollment.  The secondary aim is to evaluate what factors, if any, contributed to the 
increased accrual.  We hypothesize that increased clinical trial enrollment will be achieved 
after the onset of a prostate cancer specific clinical trial enrollment initiative in the 
Multidisciplinary Prostate Cancer Clinic at UT MD Anderson Cancer Center.  
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Methods and Materials 
Study Cohort 
Between the years 2004-2008, 1,370 men with localized prostate cancer were seen in 
the University of Texas MD Anderson Cancer Center Multidisciplinary Prostate Cancer 
Clinic (MPCC) and subsequently received treatment at MD Anderson Cancer Center.  
Prostate cancer patients seen in MPCC were self or physician referred, newly diagnosed 
(within 6 months) with localized disease and had not received definitive treatment.  Each 
MPCC was composed of at least two physicians, an urologist and a radiation oncologist.  
Patients specifically interested in trials also had the option of having a medical oncologist 
present at the MPCC visit.  In 2006, the clinical trial enrollment initiative was begun.  The 
enrollment initiative employed active recruitment of MPCC patients on to open protocols.  
Information about specific protocols and their premise were posted in the clinic area.  Based 
on eligibility criteria and appropriateness, clinicians presented the various clinical trial 
options to patients during the normal MPCC discussion of treatment options.  Patients were 
then handed a letter at the end of the visit that outlined treatment options that were discussed 
with the patient, including a list of the trials that were offered to them.   
 
Primary Outcome  
The primary outcome was enrollment in a prostate cancer clinical trial.  The 
selection of prostate cancer clinical trials open to accrual was divided into four categories: a) 
laboratory studies, b) quality of life (QOL) studies, c) procedure studies, d) novel studies.  
Two physicians (KEH, DAK) and a nurse practitioner (LM) categorized the trials.  All three 
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agreed on the final characterization for all trials. The type of clinical trial and quantity of 
clinical trials that each patient chose to participant in was recorded in the electronic medical 
record.   
Table 3: Four Categories of Clinical Trial Types 
 
Explanatory Variables 
The explanatory variables evaluated for association with enrollment in a prostate 
cancer clinical trial included: age, year of visit, self-reported race, residence and prostate 
cancer risk group.  Age was reported as a continuous variable, and then dichotomized on the 
median age of the study population (younger = younger than 64.2 years, older = older than 
64.2 years).  In this way proportional enrollment was report based on age.  Visit year was 
evaluated as both a continuous and a categorical variable.  Prostate cancer patients were 
categorized as either having visited the MPCC before the clinical trial enrollment initiative 
began in 2006 or after.  Race was evaluated as a categorized variable: Caucasian, African-
American, or Other.  Residence was categorized as either within the Houston ten-county 
metropolitan statistical area or outside of the metropolitan area.  The Houston-Sugar Land-
Baytown Metropolitan Statistical Area consists of Austin, Brazoria, Chambers, Fort Bend, 
Galveston, Harris, Liberty, Montgomery, San Jacinto and Waller counties.  Prostate cancer 
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risk group was evaluated as a categorical variable: a) low-risk, stage T1a-T2a and Gleason 
score ≤ 6 and PSA ≤ 10ng/ml; b) high-risk, stage T3-4 or Gleason score ≥ 8 or PSA > 20 
ng/mL; c) intermediate-risk, all others.  
 
Statistical Analysis 
The SAS (v 9.2) statistical software was used to analyze the outcome data.  
Descriptive statistics were generated to characterize the study cohort.  Characteristics 
included: visit year, age, ethnicity, risk group, patient residence, and clinical trial type.  
Proportional clinical trial enrollment was reported (figure 3) as well as proportional increase 
in trial enrollment (figure 6).  In addition, total clinical trial enrollment was stratified by visit 
year (figure 7), trial type (figure 4), and patient characteristics (figure 5) and by age (figure 
8).  The outcome variable was clinical trial enrollment.  There were multiple explanatory 
variables:    
 Year (as both continuous and dichotomized as 2004-2005 vs. 2006-2008) 
 Age 
 Ethnicity   
 Risk group 
 Residence    
 
For univariate analysis, logistic regression analysis was used to evaluate the 
association between clinical trial enrollment and each of the possible explanatory variables 
on a one to one basis.  Pearson’s chi square statistic was used to evaluate the significance of 
characteristics of patients who enrolled on clinical trials, to report on clinical trial enrollment 
by age group, to compare age vs. patient residence.  Pearson’s chi square statistic was also 
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used to evaluate the proportional enrollment increase broken down by trial type (see figure 
6).  
Multivariate logistic regression analysis was used to evaluate each variable’s 
association with clinical trial enrollment while controlling for the influence of the other 
covariates. To accomplish this, logistic regression modeling was used to evaluate which 
characteristic(s) co-vary with trial enrollment.  Logistic regression models were generated 
using clinical trial enrollment as the outcome variable.  Visit year was first run a continuous 
variable, then rerun including visit year as a dichotomized variable (before and after the 
implementation of a clinical trial initiative).  For both univariate and multivariate logistic 
regression analysis, the likelihood ratio chi-square was used to test for significance.  The test 
for significant difference was determined using a p-value.  P-values less than .05 were 
considered to represent a significant difference from zero…and thus a significant 
association.  Trends were defined in terms of p-value.  P-values between 0.1 - .05 were 
considered trends. 
For both univariate and multivariate analysis odds ratio (OR) and adjusted Odds 
ratios (AOR) with corresponding 95% confidence intervals were generated for each 
covariate.  The confidence interval is constructed at the 95% level in order to ensure the 
reliability of the study data gathered from this investigation.  If this study were repeated 100 
hundred times and 100 confidence intervals were constructed, then we would expect 95 of 
the hundred confidence intervals would contain the true, unknown, population parameters 
that we are trying to estimate with this study.  
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Results 
Overview 
  A total of 1,370 prostate cancer patients were seen in the MD Anderson Cancer 
Center MPCC between the years of 2004 and 2008 and subsequently received treatment at 
MD Anderson Cancer Center.  The median age at the time of visit was 64.2 years 
(interquartile range = 57.6yrs – 69.5yrs).  The vast majority of the men were Caucasian 
(82.6%).  African-American men represented 10.7% while other races made up the 
remaining 6.7% of the study population.  The study population consisted of 442 (32%) low 
risk patients, 674 (49%) intermediate risk patients, and 254 (19%) high-risk patients.  
Approximately 70% of men were permanent residents of the Houston Metropolitan area.  
Thirty percent of the men resided outside the Houston Metropolitan area or outside the state 
of Texas.  Of the 1,370 patients, 326 (24%) men were seen in MPCC before the 2006 
enrollment initiative began, and 1,044 (76%) were seen after the 2006 enrollment initiated 
was implemented.   
Of the total study population, 1,007 (73.5%) enrolled in at least one clinical trial, 
while 390 (28.5%) enrolled in 2 or more clinical trials (figure 3).  Sixty-seven percent 
enrolled in laboratory studies, 18% enrolled in QOL studies, 3.7% enrolled in procedural 
studies, and 13% enrolled in novel treatment studies.  Total patient enrollment increased 
from 38.9% before the clinical trial initiative to 84.3 % after the clinical trial initiative.  
Patient enrollment increased from 25% to 80% in laboratory studies, from 9% to 21% in 
procedural studies, from 6% to 15% in novel studies, and decreased from 8% to 2% in QOL 
studies.  Eighty-three percent of Caucasian patient were enrolled on clinical trials as 
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compared to only 11% of African-American patients, and 6% of other race patients.  Sixty-
six percent of patients who resided in Houston Metropolitan were enrolled on clinical trials, 
while only 34% of non-Houston residences were enrolled on clinical trials.  Forty-nine 
percent of patients of intermediate risk patients were enrolled on clinical trials, 32% of low 
risk patients and 19% of high risk patients were enrolled on clinical trials.  Seventy-nine 
percent of younger age patients (younger than 64.2 years) were enrolled on clinical trials vs. 
68% of older age patients (older than 64.2 years).  Sixty-five percent of patients residing in 
Houston were younger patients, 35% of non-Houston residents were younger patients.  
Seventy-four percent of Houston residence patients were older patients while 26% of non-
Houston residents were older patients. 
 
Table 4: Characteristics of 1,370 men evaluated in a multidisciplinary prostate cancer clinic 
Study Population n Median 
Total 1,370  
Age (continuous)  64.2 
 
Race/Ethnicity n % 
   Caucasian 1,132  82.6  
   African-American  146 10.7 
   Other 92 6.7 
Risk Group   
   Low risk 442 32.3 
   Intermediate risk 674 49.2 
   High risk 254 18.5 
Residence   
   Within Houston Metro 951 69.4 
   Outside Houston Metro 419 30.6 
Visit Year   
   Before Initiative 2004-2005 326 23.8 
   After Initiative 2006-2008 1,044 76.2 
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Figure 3: Total overall patient enrollment by number of trials 
 
 
 
 
 
 
 
 Figure 4: Total patient enrollment by trial type.  
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Figure 5: Characteristics of patients enrolled in clinical trials.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6:  Pre/post proportional patient enrollment by trial type 
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Figure 7: Total patient enrollment pre-initiative vs. post-initiative. 
 
 
 
 
 
 
 
 
 
Figure 8: Resident enrollment by age group 
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Univariate analysis of factors associated with enrolling in a clinical trial 
 The year of MPCC visit was evaluated as both a continuous and a dichotomized 
variable.  When visit year was evaluated as a continuous variable, patients seen in later years 
were more likely to enroll in a clinical trial (OR 2.33, 95% CI 2.09 – 2.63, p < 0.0001 per 
year increase).  Similarly, when year of visit was evaluated as a dichotomized variable, 
patients seen after the 2006 enrollment initiative were more likely to enroll in clinical trials 
that patient seen prior to the clinical trials initiative (OR 8.41, 95% CI 6.37 – 11.10 p < 
0.0001).  The overall proportion of patients enrolling in clinical trials increased from 38.9% 
before the enrollment initiative to 84.3% after (  vs.  participants, respectively).  
Residence and patient age at time of MPCC visit were also found to be associated with 
clinical trial enrollment.  Older men (OR 0.97, 95% CI 0.95 – 0.98, p < 0.0001 per year 
increase) and men living outside the Houston Metropolitan area (OR 0.54, 95% CI 0.40 – 
0.71, p <.0001) were less likely to participate in clinical trials than their younger age, locally 
residing counterparts.  Race and risk group were not shown to be associated with clinical 
trial enrollment. 
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Table 5:  Factors associated with clinical trial enrollment on univariate analysis 
 Odds Ratio (95% CI) p-Value 
Age    
   Continuous 0.97  (0.95, 0.98) <.0001 
Visit Year    
   Per year increase 2.35  (2.09, 2.63) <.0001 
   Categorical year   
      Pre-initiative Reference group Reference group 
      Post-initiative 8.41  (6.37, 11.10) <.0001 
Race/Ethnicity   
   Caucasian  Reference group Reference group 
   African-American 1.12  (0.75, 1.68) 0.572 
   Other 0.66  (0.424, 1.04) 0.074 
Residence   
   Houston metro area Reference group Reference group 
   Non-Houston metro area 0.54  (0.40, 0.71) <.0001 
Risk Group   
   Low Reference group Reference group 
   Intermediate 0.98  (0.75, 1.29) 0.887 
   High 1.05  (0.74, 1.49) 0.799 
 
 
Multivariate analysis of factors associated with enrolling in a clinical trial 
 On multivariate analysis that adjusted for age, race, residence and prostate cancer 
risk group, patients seen in the MPCC clinic in later years were more likely to enroll in 
clinical trials (AOR 2.33, 95% CI 2.07 – 2.62, p < 0.0001 per year increase.)  The year of 
the patient’s clinic visit was analyzed as a dichotomized variable, before 2006 (before 
enrollment initiative) and after 2006 (after enrollment initiative).  Men seen in clinic after 
implementation of the clinical trials enrollment initiative were more likely to enroll in a 
clinical trial than men seen before implementation of the trial enrollment initiative (AOR 
8.22, 95% CI 6.16 – 10.96, p < 0.0001).  Patient age at the time of MPCC was also found to 
be independently associated with clinical trial enrollment.  Older patients were less likely to 
 29	  
enroll in clinical trials than their younger counterparts (AOR 0.97, 95% CI 0.95 – 0.98, p < 
0.0001 per year increase).  Multivariate analysis indentified a trend for patients in the 
highest prostate cancer risk group to be more likely to participate in clinical trials (AOR 
1.43, 95% CI 0.96 – 2.13, p = 0.083) than low-risk patients.  Multivariate analysis also 
revealed that patients of ‘other’ races (namely, Hispanics, Asians, Indians and Native 
Americans) were less likely to participate in clinical trials than Caucasians patients (AOR 
0.56, 95% CI 0.34 – 0.94, p = 0.027).   
Looking at visit year as continuous variable saw similar results except for 
race/ethnicity.   Although a trend was identified as for patients of ‘other’ races to be less 
likely to participate in clinical trials than Caucasians patients  (AOR 0.60, 95% CI 0.36, p = 
0.054) it was not a statistically significant finding. 
 
Table 6:  Factors associated with clinical trial enrollment on multivariate analysis 
Visit Year (Dichotomized) 
 Odds Ratio (95% CI) p-Value 
Age 0.97  (0.95, 0.98) <.0001 
Visit Year 8.22  (6.16, 10.96) <.0001 
Race/Ethnicity   
   Caucasian  Reference group Reference group 
   African-American 0.94  (0.59, 1.48) 0.779 
   Other 0.56  (0.34, 0.94) 0.027 
Residence   
   Houston metro area Reference group Reference group 
   Non-Houston metro area 0.80  (0.58, 1.10) 0.176 
Risk Group   
   Low Reference group Reference group 
   Intermediate 1.16  (0.85, 1.58) 0.346 
   High 1.43  (0.96, 2.13) 0.083 
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Discussion 
Primary Finding 
 Our primary finding was that newly-diagnosed prostate cancer patients seen in the 
MPCC after the onset of the 2006 clinical trial enrollment initiative were more likely to 
enroll in prostate cancer clinical trials.  This result is important because of the possible 
implications it may have on enrollment patterns of patients onto prostate cancer clinical 
trials.  Identifying factors influencing participation in prostate cancer-specific clinical trials 
is critical to the development and implementation of new strategies for bolstering enrollment 
onto procedural and novel treatment investigations aimed toward improved diagnostic and 
therapeutic interventions for prostate cancer.   
 Wallace et al. (2006) looked at the accrual outcomes of a single phase III randomized 
trial comparing surgical prostatectomy vs. radiation intervention (SPIRIT) after the 
development and implementation of a multidisciplinary education session.  Similar to our 
study, an enrollment initiative was developed both to education patients more thoroughly on 
their treatment options and to facilitate increased study accrual.  Their enrollment initiative 
included an informative video about clinical trial participation following by a consultation 
with both an urologist and a radiology that explained the rationale of the study.  Before the 
development of the multidisciplinary education session, 0 of 27 eligible patients who were 
presented with the option of participating in the SPIRIT trial consented to enroll.  After 
implementation of the multidisciplinary education session, 47 sessions presented to 263 
eligible patients yielded 34 participants.  It has been showed with the SPIRIT study and this 
study as well that enhanced patient understanding of available clinical trials, treatment 
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options and the rationale for each, increases accrual.  Active recruitment techniques such as 
patient education, multidisciplinary counseling, and study advertisement tailored specifically 
to enhance accrual of clinical trials in prostate cancer is important to the future of prostate 
cancer research.  These enrollment initiatives can only be developed effectively with 
specific knowledge of what factors influence trial participation.   
Secondary Finding 
 Our secondary finding suggests that age plays an important role in clinical trial 
enrollment patterns of prostate cancer patients.  It was revealed that older patients were less 
likely to enroll in clinical trials than their younger counterparts.  There are several probable 
explanations for this finding.  Possibly, younger patients are generally healthier than older 
patients with more co-morbidities.  Older patients are less able to meet the often-restrictive 
eligibility criteria defined by some clinical trials.  Physicians may, consciously or 
unconsciously, adopt a more aggressive course of treatment with younger patients.    
A similar study conducted by Trimble et al (1994) looked at not just prostate cancer 
but also lung, colorectal, pancreatic and hematological cancers.  Trimble found that the 65+ 
male population were underrepresented in cancer treatment trials.  Of the total number of 
male cancer patients enrolled in NCI sponsored clinical cooperative group treatment trials in 
1992, only 39% were over 65 years of age.  Since then, not much progress has been made in 
accrual rates in older cancer patients.  Fifteen years later, in 2007, Stewart et al. examined 
gender, race/ethnicity, and age-based disparities in enrollment patterns specifically for 
surgical oncology trials in breast, lung, colorectal, and prostate cancer patients collectively.  
The study found that cancer patients 65-74 years old were less likely to be enrolled than 
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those 20-44 years old, making the point that the lack of proper representation of older 
patients in clinical trials is not restricted to prostate cancer alone.  It is a widespread 
problem, but it is particularly troublesome in PCa because 63% of the cases diagnosed in the 
US occur in patients 65 years or over (Mordukhovish et. al., 2010).  Thus, it is of great 
importance that the segment of the population most commonly affected by prostate cancer 
are adequately represented in clinical research aimed toward increasing the knowledge base 
and developing new/improved diagnostic and treatment methods.   
 
Tertiary Finding  
 Upon univariate analysis, it appeared as though patient residence was a contributing 
factor in clinical trial enrollment, however upon multivariate analysis this association 
dissipated.  In univariate analysis, each patient characteristic was evaluated independently 
for association with clinical trial enrollment.  However, this is not ideal since realistically, 
these characteristics can never truly exist separately.  They exist collectively and often 
interact with each other.  Each patient is a certain age, a certain race, and lives in a certain 
area, etc.  All these things may play a roll in the patient’s decision to either enroll in or not 
to enroll in a clinical trial.  Often time correlation among co-variates can mask significance 
in multivariate analysis.  This could explain why it appeared that non-Houston residents 
were less likely to enroll in clinical trails on univariate analysis.  Upon multivariate analysis, 
this association was not seen to be significant.  It might be that non-Houston residence 
younger age patients more willing to travel father for treatment.  When patient residence was 
crossed with patient age group it was noted that 35% of the non-Houston residents who 
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enrolled in Clinical Trials were younger patient as compared to only 26% of the non-
Houston residents were older patients.  It should also be noted that part of the inclusion 
criteria for this study requires that patients be seen and treated in the UT MD Anderson 
Cancer Center’s MPCC regardless of whether they chose to be treated on-study or off-study.  
 
Trends 
 Analysis of the dataset showed two additional findings that did not meet the criteria 
for significance, nevertheless, they are worthy of note.  There was a trend seen for high-risk 
PCa patients to be more likely to enroll in clinical trials than the low risk patients.  This 
study also identified a trend for PCa patients of ‘Other’ races (namely, Hispanics, Asians, 
Indians and Native Americans) to be less likely to participate in clinical trials than 
Caucasian patients.  There are several lines of reasoning which could explain these trends. 
 High-risk PCa patients were categorized as such because their PSA level, Gleason 
score, and T-stage suggests that these patients had an increased risk of tumor recurrence 
following treatment.  A patient’s risk group status often guides the physician in making the 
appropriate treatment recommendations.  Clinical trials, because they are often testing 
unproven therapies, are generally considered more aggressive than the proven standard-of-
care options.  It might be that physicians recommend what they view as a more aggressive 
treatment option to high-risk PCa patients more often than to low risk patients because high 
risk patient are expected to have a worse prognosis.  In turn, a high-risk patient might be 
more willing to be treated on a PCa clinical trial because they perceive it as a more 
aggressive approach to eradicating their cancer. 
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 In the US, the observed incidence of prostate cancer is lower in all the other races 
(Hispanic, Native Americans, Asians and Indians) as compared to Caucasians (Jemal, 2010).  
PCa incidence is lower among Hispanic races and lower still in Native and Asian Americans 
Caucasians and African Americans, thus the pool of potential patients is smaller.  Asian 
Americans and Native Americans have the lowest incidence of PCa among the ethnic 
groups.  A smaller population base of PCa patients means fewer trial candidates and 
therefore fewer clinical trials enrollees.  There has also been research suggesting that 
different social values and concerns (such as fear of loss of virility and sexual function, fears 
of exploitation, and the spiritual/religious implications of treatment) among certain ethnic 
groups compel some to delayed diagnosis and treatment, or opt to forgo diagnosis/treatment 
altogether which could contribute to their underrepresentation in clinical trials.  Socio-
economic disparities among different ethnic groups could also explain the lower 
participation of ‘other’ race PCa patients in clinical trials.  Lack of income, education and 
adequate health insurance likely contributes to the lack of access to the full range of therapy 
options, including, unfortunately clinical trial enrollment (particularly trials that require 
costly out-of-pocket expenditures). 
  
Strengths and Limitations 
The results of our study, while viable, lack a certain degree of generalizability.  This 
is in part because data collection was confined to one site, the UT MD Anderson Cancer 
Center MPCC.  There is also an unbalanced racial/ethical distribution among the study 
cohort.  The vast majority of the participants were Caucasian males.  As is true of clinical 
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trials in general, minorities are not adequately represented.  This is particularly concerning 
to our study, considering African-American minorities have a disproportionately increased 
risk and incidence of prostate cancer and yet they remain underrepresented in prostate 
cancer clinical trials research.  Future studies looking at accrual patterns in PCa patients 
should seek to include multiple study sites in order to broaden the variety of patients and to 
possibly recruit a higher percentage of minorities.  Specific strategies should be 
implemented to target increasing clinical trial enrollment among African-Americans and 
other minority patients.  This research is needed because some factors associated with 
clinical trials enrollment may vary with ethnicity.  In addition, socioeconomic factors, which 
could possibly play an important roll in clinical trial enrollment particularly in minority 
populations, were not explored in this study.   
The way in which the study was designed captures the trial type and number of 
clinical trials each patient chose to participate in, but not the total number and type of trials 
each patient was initially offered.  Additionally, the trial design included a large 
heterogeneity of clinical trials, (laboratory studies, QOL, procedural and novel studies).  It 
might be interesting and possibly more informative to examine one specific trial type.  
Another consideration not taken into account by the experimental design is the continuity of 
trial offerings over time.  It could be that more trials were available after the enrollment 
initiative began.  If there were less trial offerings available for patients seen before the 
initiative began, then there was a slight handicap to trial enrollment inherent to the 
experimental design, which was not controlled for.  This begs the question, did trial 
enrollment increased because of the enrollment initiative or because of increased trial 
availability after the initiative.   
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Another similar issue is the number of each trial type available over time.  Were the 
pool of potential clinical trials saturated with a majority of one trial type (ex. lab studies) at 
certain points of time, while other trial types were in short supply (QOL)?  The fact that 
QOL studies were the only trial type that decreased rather than increased in enrollment after 
the enrollment initiative could be explained by a lack of availability of QOL trials in those 
years rather than a conscience decision by patients against the trial type.  Uncontrolled 
variables in the study design such as trail availability and trial continuity over time tend to 
weaken the confidence is the study’s outcome.   
The major strength of the study was that it captured prostate cancer patients seen in 
the MPCC over a span of several years.  A second strength of the study is that by having all 
data collected at one site there is better completeness and continuity of data.  Examining an 
enrollment initiative impact on clinical trial accrual patterns at pre and post time points and 
then running a statistical analysis of the study data is a very straightforward study design.  
The outcome and conclusions that are drawn from the data are likewise unambiguous and 
can be readily incorporated into future investigations. 
 
Recommendations 
In future studies, there is a need to include multiple study sites in the collection of 
data.  A conscious effort should be made to target minority enrollment in clinical trials, 
perhaps even focus entirely on minority recruitment with a newly designed enrollment 
initiative directed specifically toward under-represented ethnic populations.  Making these 
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two adjustment to future trials would help to increase the generalizeability of the study 
outcome(s). 
Additional alterations should be made in the study design in order to control for 
clinical trial availability and trial type availability over time.  It would strengthen the study’s 
internal validity if the quantity of trails available were held constant throughout the study.  
Likewise, an equal quantity of each trial type should be available throughout the study so 
that any increase or decrease in trial enrollment observed could be more confidently 
attributed to the enrollment initiative and not muddied by uncontrolled competing variables. 
It might be a worthwhile endeavor to take a more microscopic approach to the 
subject matter.  It would be interesting to focus on one specific trial type or even one 
individual trial and design an enrollment initiative tailored to enhance accrual on to just that 
trial type or that one clinical trial.  This design might be more time-consuming.  A pilot 
period may be required, wherein the study is run specifically to gauge patient interest in 
and/or initial reaction to participation in the study.  Based on patient reactions and /or 
recommendations (captured via a survey or questionnaire) a suitable enrollment initiative 
could then be tailored to meet the needs of the individual trial or trial type.   
 
Conclusion 
Clinical trial enrollment in our multidisciplinary clinic was substantially higher than 
seen nationally in adult cancer patients.  Enrollment rates increased after introduction of a 
clinical trial initiative.  We further conclude that age plays an important role in clinical trial 
enrollment patterns of prostate cancer patients.  We speculate we achieved high enrollment 
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rates because 1) specific trials are discussed at time of treatment recommendations, 2) we 
provide a letter documenting offered trials and 3) we introduce patients to the research team 
at the same clinic visit if they are interested in trial participation.   
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